Armaceutica, Inc.
🇺🇸United States
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Phase 2
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Armaceutica, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05291390
- Locations
- 🇸🇳
Dalal Jamm Hospital, Guediawaye GOL SUD, Dakar, Senegal
© Copyright 2025. All Rights Reserved by MedPath